PTK2B and neoplasm: Molecular imaging such as PET coupled with suitable selective labeled bioprobes that target specific PTKs has the potential to resolve some of the above mentioned obstacles by: 1) noninvasively determining whether the target protein is expressed in a specific tumor and its metastasis; 2) monitoring target-drug binding and receptor occupancy in vivo; 3) determining duration of PTK inhibition in vivo; and 4) potentially identifying the existence of a primary or secondary mutation leading to either drug interaction or loss of PTK recognition by the drug.